• Rachel Joujon-Roche, Pooja Dave, Peter Tretiakov, Kimberly Mcfarland, Jamshaid Mir, Tyler K Williamson, Bailey Imbo, Oscar Krol, Jordan Lebovic, Andrew J Schoenfeld, Shaleen Vira, Renaud Lafage, Virginie Lafage, and Peter G Passias.
• Department of Orthopaedics, NYU Langone Medical Center-Orthopaedic Hospital, New York, NY.
• Spine. 2024 Feb 15; 49 (4): 255260255-260.

Study DesignThis was a retrospective study.ObjectiveTo assess the impact of surgical costs on patient-reported outcomes in adult spinal deformity (ASD).Summary Of Background DataWith increased focus on delivering cost-effective health care, interventions with high-resource utilization, such as ASD surgery, have received greater scrutiny.Materials And MethodsASD patients aged 18 years and older with BL and 2-year data were included. Surgical costs were calculated using the 2021 average Medicare reimbursement by Current Procedural Terminology code. Costs of complications and reoperations were intentionally excluded. Patients were ranked into tertiles by surgical cost: highest surgical costs (HC) and lowest surgical costs (LC). They were propensity score matched to account for differences in baseline age and deformity. Bivariate logistic regressions assessed odds of achieving outcomes.ResultsFour hundred twenty-one patients met inclusion (60.7 yr, 81.8% female, Charlson Comorbidity Index: 1.6, 27.1 kg/m 2 ), 139 LC and 127 HC patients. After propensity score matching, 102 patients remained in each cost group with an average reimbursement of LC: $12,494 versus HC: $29,248. Matched cohorts had similar demographics and baseline health-related quality of life. Matched groups had similar baseline sagittal vertical axis (HC: 59.0 vs. LC: 56.7 mm), pelvic incidence and lumbar lordosis (HC: 13.1 vs. LC: 13.4°), and pelvic tilt (HC: 25.3 vs. LC: 22.4°). Rates of complications were not significantly different between the cost groups. Compared with the LC group, by 2 years, HC patients had higher odds of reaching substantial clinical benefit in Oswestry Disability Index [odds ratio (OR): 2.356 (1.220, 4.551), P =0.011], in Scoliosis Research Society-Total [OR: 2.988 (1.515, 5.895), P =0.002], and in Numerical Rating Scale Back [OR: 2.739 (1.105, 6.788), P =0.030]. Similar findings were appreciated for HC patients in the setting of Schwab deformity outcome criteria.ConclusionsAlthough added cost did not guarantee an ideal outcome, HC patients experienced superior patient-reported outcomes compared with LC patients. Although cost efficiency remains an important priority for health policy, isolating cost reduction may compromise outcomes and add to future costs of reintervention, particularly with more severe baseline deformity.Level Of Evidence3.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

20 keywords...

hide…